Equitec Specialists’s Cardlytics CDLX Stock Holding History

Equitec Specialists’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50	Closed	-$35K	–	221
2020 Q3	$35K	Buy	+50	New	+$36.4K	﹤0.01%	128

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Equitec Specialists's CDLX Position: Q4 2020 in Review

Equitec Specialists sold out of Cardlytics (CDLX) in Q4 2020, closing a stake of 50 shares — an estimated $35K sold.

Equitec Specialists first reported a position in CDLX in Q3 2020 and held it in 1 quarter. The position peaked at $35K in Q3 2020. 195 funds tracked by Wall St. Rank hold CDLX as of Q4 2020.

Equitec Specialists reported no remaining Cardlytics position as of Q4 2020 after selling out during the quarter.
Equitec Specialists sold 50 Cardlytics shares in Q4 2020, an estimated $35K.
Equitec Specialists first reported a position in Cardlytics in Q3 2020 and held it in 1 quarter.
Equitec Specialists's Cardlytics position peaked at $35K in Q3 2020.
195 funds tracked by Wall St. Rank held Cardlytics as of Q4 2020.

Based on Equitec Specialists's 13F filing for Q4 2020, filed 26 Jan 2021.